1063613-39-7

Basic information

• Product Name: [2-(2-bromo-3-methyl-6-nitro-phenyl)-vinyl]-dimethyl-amine
• Synonyms: [2-(2-bromo-3-methyl-6-nitro-phenyl)-vinyl]-dimethyl-amine
• CAS NO: 1063613-39-7
• Molecular Weight: 285.14
• Mol File: 1063613-39-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: [2-(2-bromo-3-methyl-6-nitro-phenyl)-vinyl]-dimethyl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: [2-(2-bromo-3-methyl-6-nitro-phenyl)-vinyl]-dimethyl-amine(1063613-39-7)
• EPA Substance Registry System: [2-(2-bromo-3-methyl-6-nitro-phenyl)-vinyl]-dimethyl-amine(1063613-39-7)

Safety Data

• Hazardous Substances Data: 1063613-39-7(Hazardous Substances Data)

Upstream product

• 5815-08-7 tert-Butoxybis(dimethylamino)methane 
• 60956-25-4 2-bromo-1,3-dimethyl-4-nitrobenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 576-22-7 2-Bromo-m-xylene 

Downstream Products

• 610794-15-5 4-bromo-5-methyl-1H-indole 
• 1449580-84-0 2-(5-methyl-1H-indol-4-yl)-5-[4-(3,3-dimethylpiperazin-1-yl)phenyl]-1,3-oxazole-4-carboxylic acid amide 
• 693286-67-8 5-methylindole-4-boronic acid 

Relevant articles and documents

AURORA AND FLT3 KINASES MODULATORS

The invention provides a compound having the formula (1): and salts thereof; wherein: R1 is hydrogen or C1-2 alkyl; and R2, R3 and R4 are the same or different and each is selected from hydrogen, C1-2 alkyl, fluorine, chlorine, C1-2 alkoxy and trifluoromethyl, provided that no more than two of R2, R3 and R4 are other than hydrogen. Also provided are pharmaceutical compositions containing the compounds and their use in medicine, and in particular in the treatment of cancer.

4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES

4,5-disubstituted-2-arylpyrimidines of Formula (I) and Formula (II) are provided: wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 4,5-disubstituted-2-arylpyrimidines, which are useful as probes for the localization of C5a receptors.